Shots:

• The P-II SWOG S1500/PAPMET trial involves assessing cabometyx (60 mg- qd with dose reductions to 40 & 20mg )- crizotinib- and savolitinib vs sunitinib in a ratio (1:1:1:1) for patients with advanced or metastatic PRCC
• The results demonstrated significant improvement in PFS. The trial met its 1EP’s shows mPFS (9.0 mos. vs 5.6 mos.); ORR (23% vs 4%) mOS (20.0 mos. vs 16.4 mos.)
• The findings were presented at the 2021 ASCO GU and simultaneously published in The Lancet

 ­ Ref: Exelixis | Image: Exelixis